Kieron Dunleavy

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 853 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma

Kieron Dunleavy, Stefania Pittaluga, Lauren S. Maeda et al. · New England Journal of Medicine · 2013 · 561 citations · Full text

Medicine, Immunology, Oncology +15

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

Kieron Dunleavy, Stefania Pittaluga, Myron S. Czuczman et al. · Blood · 2009 · 500 citations · Full text

Medicine, Oncology, Pharmacology +16

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Michail S. Lionakis, Kieron Dunleavy, Mark Roschewski et al. · Cancer Cell · 2017 · 499 citations · Full text

Medicine, Oncology, Pharmacology +14

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

Mark Roschewski, Kieron Dunleavy, Stefania Pittaluga et al. · The Lancet Oncology · 2015 · 458 citations · Full text

Medicine, Oncology, Radiology +17